2539 related articles for article (PubMed ID: 6767404)
1. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
2. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
3. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
4. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
5. Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation.
Shaaban MM; Elwan SI; el-Kabsh MY; Farghaly SA; Thabet N
Contraception; 1984 Nov; 30(5):421-30. PubMed ID: 6440738
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
7. Lipid and biochemical changes after low-dose oral contraception.
Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
[TBL] [Abstract][Full Text] [Related]
8. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
Wilson ES; Cruickshank J; McMaster M; Weir RJ
Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
[TBL] [Abstract][Full Text] [Related]
9. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
Carlborg L
Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
11. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
12. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
Skouby SO; Wagner HH; Andersen O
Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
[TBL] [Abstract][Full Text] [Related]
13. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
15. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
16. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
17. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
[TBL] [Abstract][Full Text] [Related]
18. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
Spellacy WN
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
[TBL] [Abstract][Full Text] [Related]
20. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate.
Klove KL; Roy S; Lobo RA
Contraception; 1984 Apr; 29(4):319-24. PubMed ID: 6235099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
